Publication of clinical trials supporting successful new drug applications: a literature analysis.
<h4>Background</h4>The United States (US) Food and Drug Administration (FDA) approves new drugs based on sponsor-submitted clinical trials. The publication status of these trials in the medical literature and factors associated with publication have not been evaluated. We sought to deter...
Main Authors: | Kirby Lee, Peter Bacchetti, Ida Sim |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2008-09-01
|
Series: | PLoS Medicine |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18816163/?tool=EBI |
Similar Items
-
Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
by: Kristin Rising, et al.
Published: (2008-11-01) -
Correction: Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation.
by: Kristin Rising, et al.
Published: (2009-01-01) -
The Success Rate of New Drug Development in Clinical Trials: Crohn’s Disease
by: Jayson Lee Parker, et al.
Published: (2010-06-01) -
Challenges of Investigator-initiated Clinical Trials to Support
the New Drug Development
by: Hua BAI, et al.
Published: (2022-07-01) -
Randomized controlled trial data for successful new drug application for rare diseases in the United States
by: Yosuke Kubota, et al.
Published: (2023-04-01)